They are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Their mission is to improve patient outcomes and save lives. To achieve their mission, they are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions. Their lead development program is a novel, first-in-class, targeted immuno-oncology gene therapy for the treatment of multiple cancers. They have partnered with City of Hope, or COH, for CpG-STAT3siRNA, a STAT3 inhibitor gene therapy. In pre-clinical testing at City of Hope, their STAT3 inhibitor has successfully reduced growth and metastasis of various pre-clinical tumor models, including melanoma, and colon and bladder cancers, as well as leukemia and lymphoma. An investigational new drug application, or IND, for their STAT3 inhibitor for B-cell lymphoma is currently anticipated to be filed with the United States Food and Drug Administration, or FDA, in Q4 2020. They currently anticipate that a first-in-human Phase 1 clinical trial for B-cell lymphoma will commence in Q1 2021.